IL133087A0 - Conjugated peptide nucleic acids having enhanced cellular uptake - Google Patents

Conjugated peptide nucleic acids having enhanced cellular uptake

Info

Publication number
IL133087A0
IL133087A0 IL13308798A IL13308798A IL133087A0 IL 133087 A0 IL133087 A0 IL 133087A0 IL 13308798 A IL13308798 A IL 13308798A IL 13308798 A IL13308798 A IL 13308798A IL 133087 A0 IL133087 A0 IL 133087A0
Authority
IL
Israel
Prior art keywords
nucleic acids
peptide nucleic
cellular uptake
enhanced cellular
conjugated peptide
Prior art date
Application number
IL13308798A
Original Assignee
Nielsen Peter E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nielsen Peter E filed Critical Nielsen Peter E
Publication of IL133087A0 publication Critical patent/IL133087A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13308798A 1997-05-28 1998-05-28 Conjugated peptide nucleic acids having enhanced cellular uptake IL133087A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86476597A 1997-05-28 1997-05-28
PCT/US1998/010804 WO1998053801A1 (en) 1997-05-28 1998-05-28 Conjugated peptide nucleic acids having enhanced cellular uptake

Publications (1)

Publication Number Publication Date
IL133087A0 true IL133087A0 (en) 2001-03-19

Family

ID=25344022

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13308798A IL133087A0 (en) 1997-05-28 1998-05-28 Conjugated peptide nucleic acids having enhanced cellular uptake

Country Status (7)

Country Link
EP (1) EP1003480A4 (en)
JP (1) JP2001501975A (en)
AU (1) AU745309B2 (en)
CA (1) CA2291839A1 (en)
IL (1) IL133087A0 (en)
NZ (1) NZ501289A (en)
WO (1) WO1998053801A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6472209B1 (en) 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6723560B2 (en) 1998-10-08 2004-04-20 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
DE19909373A1 (en) * 1999-03-03 2000-10-05 Ugichem New PNA monomers, resulting PNA oligomers and their use
DE10038169A1 (en) * 2000-08-04 2002-03-07 November Ag Molekulare Medizin Synthetic particle for marking a substance
EP1543019A2 (en) * 2002-09-11 2005-06-22 Santaris Pharma A/S Modified pna molecules
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
WO2011005761A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc Novel nucleic acid prodrugs and methods use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
CN107365339A (en) 2011-07-19 2017-11-21 波涛生命科学有限公司 The method for synthesizing functionalization nucleic acid
CN112007045A (en) 2012-07-13 2020-12-01 波涛生命科学有限公司 Chiral control
KR101835401B1 (en) 2012-07-13 2018-03-08 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. Chiral nucleic acid adjuvant
EP2872485B1 (en) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Asymmetric auxiliary group
JPWO2015108047A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
BR112016016400A2 (en) 2014-01-16 2017-10-03 Wave Life Sciences Ltd COMPOSITIONS OF CHIRALLY CONTROLLED OLIGONUCLEOTIDES, THEIR USE, THEIR PHARMACEUTICAL COMPOSITION, AND METHODS
DE102014007158A1 (en) * 2014-05-16 2015-11-19 Ugichem Gmbh New peptide-nucleic acid monomers and oligomers
PE20171238A1 (en) 2014-06-24 2017-08-24 Shire Human Genetic Therapies STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR NUCLEIC ACIDS ADMINISTRATION
AU2020315947A1 (en) * 2019-07-24 2022-03-10 The Trustees Of Columbia University In The City Of New York Methods and compositions for treating cancer using peptide nucleic acid-based agents
CN114315835B (en) * 2021-11-30 2023-03-03 华南农业大学 A kind of 6-benzyl adenine hapten, artificial antigen, antibody and its preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5705333A (en) * 1994-08-05 1998-01-06 The Regents Of The University Of California Peptide-based nucleic acid mimics(PENAMS)
WO1996011205A1 (en) * 1994-10-06 1996-04-18 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
WO1996019240A1 (en) * 1994-12-21 1996-06-27 Novartis Ag Oligonucleotide-dendrimer conjugates
WO1997014026A2 (en) * 1995-10-12 1997-04-17 Dako A/S Method for detecting multiple copies of a repeat sequence in a nucleic acid molecule

Also Published As

Publication number Publication date
AU7602198A (en) 1998-12-30
EP1003480A1 (en) 2000-05-31
EP1003480A4 (en) 2002-04-17
JP2001501975A (en) 2001-02-13
WO1998053801A1 (en) 1998-12-03
NZ501289A (en) 2001-06-29
AU745309B2 (en) 2002-03-21
CA2291839A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
IL133087A0 (en) Conjugated peptide nucleic acids having enhanced cellular uptake
PL344341A1 (en) Peptides
IL136290A0 (en) Improved interferon polymer conjugates
EP1012260A4 (en) Interleukin-20
GB9827348D0 (en) Natriuretic peptide
GB2332660B (en) Improved deflector
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
IL132379A (en) Multi-frequency antenna
EP0926691A4 (en) Automotive combination switch
ZA98642B (en) Immune-modulation with amino acids
GB9718110D0 (en) Peptides
GB9825854D0 (en) Peptide
GB9700154D0 (en) Peptides
GB9812675D0 (en) Peptides
ZA984322B (en) Sucrose-binding proteins
GB9720784D0 (en) Protein
GB9807890D0 (en) Peptides
GB9719486D0 (en) Electrically propelled vehicle
GB9713146D0 (en) Peptides
GB9706556D0 (en) Peptides
GB9701024D0 (en) Peptides
GB9720995D0 (en) Nucleic acids
GB9818368D0 (en) Vitronectin-derived peptides
GB9827603D0 (en) Peptides